Fierce Pharma Asia—Congress' US-China biotech report; NIH's database ban; GSK's ABL neuroscience deal

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. The NIH has blocked access to some health and genomics databases for China and other countries. GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more.1. Congressional commission urges $15B, more action to maintain US biotech advantage over China The U.S. Congress’ National Security Commission on Emerging Biotechnology recommends that the government dedicate $15 billion to the biotechnology sector over the next five years while warning that the U.S. is “dangerously close to falling behind China” in this field. The report contains various measures that Congress could enact to “leverage our capital markets to advance national biotechnology priorities.” 2. NIH blocks researchers in China, Russia and other countries from multiple databasesThe National Institutes of Health has abruptly blocked access from China, Russia, Iran...